We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current TBPH market cap is 471.58M. The company's latest EPS is USD -1.1224 and P/E is -8.56.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 15.69M | 17.57M | 14.5M | 14.26M | 16.87M |
| Operating Income | -8.76M | -6.24M | -11.21M | -12.75M | -9.28M |
| Net Income | -8.95M | -8.51M | -11.66M | -16.53M | -12.7M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 73.41M | 71.86M | 55.31M | 51.35M | 57.42M |
| Operating Income | -218.21M | -229.32M | -153.8M | -91.96M | -56.04M |
| Net Income | -236.46M | -278.02M | -199.43M | 872.13M | -55.19M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 413.59M | 382M | 371.31M | 362.03M | 356.11M |
| Total Liabilities | 167.46M | 169M | 166.44M | 168.34M | 170.45M |
| Total Equity | 246.13M | 213M | 204.87M | 193.69M | 185.65M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 408.83M | 469.06M | 374.82M | 607.4M | 382M |
| Total Liabilities | 632.67M | 772.81M | 713.39M | 165.6M | 169M |
| Total Equity | -223.84M | -303.75M | -338.57M | 441.8M | 213M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -26.14M | -27M | -1.02M | -5.44M | -10.63M |
| Investing | -32.02M | -32.7M | 17.03M | 14M | -3.4M |
| Financing | -168.32M | -198.93M | -1.72M | -1.76M | -2.13M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -238.2M | -250.4M | -207.86M | -186.99M | -27M |
| Investing | -83.05M | 10.72M | 124.49M | 1.15B | -32.7M |
| Financing | 1.29M | 251.62M | 91.86M | -758.81M | -198.93M |
| Market Cap | 471.58M |
| Price to Earnings Ratio | -8.56 |
| Price to Sales Ratio | 8.23 |
| Price to Cash Ratio | 11.95 |
| Price to Book Ratio | 2.22 |
| Dividend Yield | - |
| Shares Outstanding | 49.17M |
| Average Volume (1 week) | 221.3k |
| Average Volume (1 Month) | 218.62k |
| 52 Week Change | -13.29% |
| 52 Week High | 11.71 |
| 52 Week Low | 7.44 |
| Spread (Intraday) | 1.49 (14.42%) |
| Company Name | Theravance Biopharma Inc |
| Address |
p.o. box 309 george town KY1-1104 |
| Website | https://www.theravance.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
